117 related articles for article (PubMed ID: 19783381)
1. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs.
Schuster CR; Barthwell AG; Henningfield JE
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S4-8. PubMed ID: 19783381
[No Abstract] [Full Text] [Related]
2. Risk management and post-marketing surveillance of CNS drugs: an introduction.
Balster RL; Johanson CE; Walsh SL
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805
[No Abstract] [Full Text] [Related]
3. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
4. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
5. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
Leiderman DB
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
[TBL] [Abstract][Full Text] [Related]
6. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.
Johanson CE; Balster RL; Henningfield JE; Schuster CR; Anthony JC; Barthwell AG; Coleman JJ; Dart RC; Gorodetzky CW; O'Keeffe C; Sellers EM; Vocci F; Walsh SL
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1(Suppl 1):S65-71. PubMed ID: 19783383
[TBL] [Abstract][Full Text] [Related]
7. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
8. [Correspondents in post- marketing surveillance, drug dependence surveillance, and toxicovigilance: definition and roles].
Rioufol C; Vial T; Pulce C; Descotes J
Therapie; 2002; 57(2):201-4. PubMed ID: 12185974
[No Abstract] [Full Text] [Related]
9. Resting assured: risk management in the prescription of controlled substances.
Longo LP
WMJ; 1999; 98(1):23-9. PubMed ID: 10050150
[No Abstract] [Full Text] [Related]
10. Risk identification, risk assessment, and risk management of abusable drug formulations.
Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201
[TBL] [Abstract][Full Text] [Related]
11. Case histories in pharmaceutical risk management.
McCormick CG; Henningfield JE; Haddox JD; Varughese S; Lindholm A; Rosen S; Wissel J; Waxman D; Carter LP; Seeger V; Johnson RE
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S42-55. PubMed ID: 19767156
[TBL] [Abstract][Full Text] [Related]
12. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
13. [Post-marketing surveillance systems for psychoactive prescription drug abuse].
Nordmann S; Frauger E; Pauly V; Rouby F; Mallaret M; Micallef J; Thirion X
Therapie; 2011; 66(3):263-72. PubMed ID: 21819810
[TBL] [Abstract][Full Text] [Related]
14. Harm reduction is a good label for a criterion all drug programs should meet.
Maccoun RJ
Addiction; 2009 Mar; 104(3):341-2; discussion 345-6. PubMed ID: 19207338
[No Abstract] [Full Text] [Related]
15. Dutch policy on the management of drug-related problems: an Anglo-Dutch debate.
Br J Addict; 1989 Sep; 84(9):989-97. PubMed ID: 2790278
[No Abstract] [Full Text] [Related]
16. WHO expert committee on drug dependence.
World Health Organ Tech Rep Ser; 1995; 856():1-17. PubMed ID: 8928523
[No Abstract] [Full Text] [Related]
17. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
Noah BA; Brushwood DB
J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
[TBL] [Abstract][Full Text] [Related]
18. Harm reduction and the global drug control regime: contemporary problems and future prospects.
Bewley-Taylor DR
Drug Alcohol Rev; 2004 Dec; 23(4):483-9. PubMed ID: 15763753
[TBL] [Abstract][Full Text] [Related]
19. Conference on abuse liability assessment of CNS drugs.
Schuster CR; Henningfield J
Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S1-4. PubMed ID: 12759193
[No Abstract] [Full Text] [Related]
20. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
